Electrocardiographic findings of palonosetron in cancer patients

Supportive Care in Cancer

Volumn 20, Issue 7, 2012, Pages 1435-1439

  Gonullu, Guzin ^a   Demircan, Sabri ^a   Demirag, Mustafa Kemal ^a   Erdem, Dilek ^a   Yucel, Idris ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

5 HT 3 receptor antagonist; P wave; Palonosetron; QRS complex; QT interval

Indexed keywords

PALONOSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CORRECTED QT DISPERSION; CORRECTED QT INTERVAL; DIASTOLIC BLOOD PRESSURE; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; P WAVE; PR INTERVAL; PREMEDICATION; PRIORITY JOURNAL; QRS COMPLEX; QT DISPERSION; SIDE EFFECT; SOLID TUMOR; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINUCLIDINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TIME FACTORS; VOMITING; YOUNG ADULT;

EID: 84863971046     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1226-5     Document Type: Article

References (33)

1. Navari RM (2009) Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol 5:1577-1586
2. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Grève J, Diaz-Rubio E, Seitz JF et al (1996) Adouble-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A:807-813
3. Navari RM (2003) Pathogenesis-based treatment of chemotherapyinduced nausea and vomiting-two new agents. J Support Oncol 1:89-103
4. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, singledose trial versus dolasetron. Cancer 98:2473-2482
5. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
6. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35-41
7. Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X, Zhang H, Liu D, Zhang H (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Canc 17:99-102
8. Watanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M (1995) Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Canc Chemother Pharmacol 35:278-282
9. Boike SC, Ilson B, Zariffa N, Jorkasky DK (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. AmJ Health Syst Pharm 54:1172-1176
10. Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W (1996) Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 28:53-59
11. Perzanowski C, Ho AT, Jacobson AK (2005) Increased P-wave dispersion predicts recurrent atrial fibrillation after cardioversion. J Electrocardiol 38:43-46
12. Chen A, Kusumoto FM (2004) QT dispersion: much ado about something? Chest 125:1974-1977
13. Day CP, McComb JM, Campbell RW (1990) QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 63:342-344
14. Perkiomaki JS, Huikuri HV, Koistinen JM, Makikallio T, Castellanos A, Myerburg RJ (1997) Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. Am Coll Cardiol 30:1331-1338
15. Morganroth J (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res Found Workshop 59:171-184
16. Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7:353-370
17. Yavas O, Yazici M, Eren O, Boruban C, Artac M, Genc M (2008) The acute effect of tropisetron on ECG parameters in cancer patients. Support Care Canc 16:1011-1015
18. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF (1995) A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35:705-712
19. Gray GW, McLellan TM, Ducharme MB (1996) Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 67:759-761
20. Jantunen IT, Kataja VV, Muhonen TT, Parviainen T (1996) Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37:502-504
21. Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, Reeves JA, Porter LL, Benedict CR, Hahne WF (1997) Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 3:45-51
22. Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF (1997) Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer 79:1216-1224
23. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapyinduced Emesis Prevention Group. J Clin Oncol 14:2242-2249
24. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966-2973
25. Buyukavci M, Olgun H, Ceviz N (2005) The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28:201-204
26. Keefe DL (2002) The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern? Oncologist 7:65-72
27. Nishio H, Fujii A, Nakata Y (1996) Re-examination for pharmacological properties of serotonin-induced tachycardia in isolated guinea-pig atrium. Behav Brain Res 73:301-304
28. Aapro M, Rabaeus MR (2005) The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28:634-635
29. Sevimli S, Arslan S, Gündoǧdu F, Aksakal E, Tas H, Gürlertop Y et al (2007) Konjestif kalp yetersizliǧi olan hastalarda karvedilol tedavisi QT dispersiyonunda düzelme saǧlamaktad?r. Turk Kardiyol Dern Ars 35:284-288
30. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin A et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449
31. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15:330-337
32. Coop AJ (2003) Comment: electrocardiogrphic and cardiovascular effects of the 5-hydroxytryptamine-3 resector antagonists. Ann Pharmacother 37:1918
33. Aapro MS, Macciocchi A, Gridelli C (2005) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 3:369-374